ALL |
META-ANALYSIS |
CITATIONS |
|
Meta-Analysis of Program Effects | ||||||||||||
Outcomes measured | No. of effect sizes | Treatment N | Adjusted effect size(ES) and standard error(SE) | Unadjusted effect size (random effects model) | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
ES | SE | Age | ES | p-value | ||||||||
Anxiety disorder Clinical diagnosis of an anxiety disorder (e.g., general anxiety, panic, social anxiety, obsessive compulsive disorder) or symptoms measured on a validated scale. |
2 | 101 | -0.195 | 0.246 | 22 | -0.195 | 0.427 | |||||
Major depressive disorder Clinical diagnosis of major depression or symptoms measured on a validated scale. |
2 | 116 | 0.101 | 0.663 | 22 | 0.101 | 0.878 | |||||
Global functioning How well individuals (typically those who are developmentally disabled or seriously mentally ill) have adapted to activities of daily living. |
3 | 142 | 0.121 | 0.229 | 22 | 0.121 | 0.597 | |||||
Hospitalization (psychiatric) Admission to a psychiatric ward or hospital. |
1 | 59 | -0.326 | 0.397 | 22 | -0.326 | 0.411 | |||||
Psychosis symptoms (positive) Symptoms of psychosis that are experienced in addition to normal function (e.g., delusions, hallucinations, or agitation) measured on a validated scale, for individuals with serious mental illness. |
2 | 54 | -0.311 | 0.294 | 22 | -0.311 | 0.290 | |||||
Psychiatric symptoms Mental health symptoms (such as symptoms of psychosis) in individuals with serious mental illness, measured on a validated scale. |
3 | 180 | -0.287 | 0.172 | 22 | -0.287 | 0.096 | |||||
Psychosis symptoms (negative) Symptoms of psychosis that reflect a decrease or loss of normal function (e.g., diminished emotional expression, lack of motivation) measured on a validated scale, for individuals with serious mental illness. |
2 | 46 | 0.165 | 0.290 | 22 | 0.165 | 0.571 | |||||
Psychosis onset Initial development or onset of a diagnosed psychotic disorder such as schizoaffective disorder or schizophrenia. |
5 | 344 | -0.653 | 0.275 | 22 | -0.653 | 0.018 |
Addington, J., Epstein, I., Liu, L., French, P., Boydell, K M., & Zipursky, R.B. (2011). A randomized controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis. Schizophrenia Research, 125(1), 54-61.
Ising, H.K., Kraan, T.C., Rietdijk, J., Dragt, S., Klaassen, R.M., Boonstra, N., Nieman, D.H., . . . van der Gaag, M. (2016). Four-year follow-up of cognitive behavioral therapy in persons at ultra-high risk for developing psychosis: The Dutch Early Detection Intervention Evaluation (EDIE-NL) Trial. Schizophrenia Bulletin, 42(5), 1243-1252.
McGorry, P.D., Nelson, B., Phillips, L.J., Yuen, H.P., Francey, S.M., Thampi, A., Berger, G.E., . . . Yung, A.R. (2013). Randomized controlled trial of interventions for young people at ultra-high risk of psychosis: twelve-month outcome. The Journal of Clinical Psychiatry, 74(4), 349-356.
Morrison, A.P., French, P., Walford, L., Lewis, S.W., Kilcommons, A., Green, J., et al. (2004). Cognitive therapy for the prevention of psychosis in people at ultra-high risk: Randomised controlled trial. The British Journal of Psychiatry, 185(4), 291-297.
Morrison, A.P., French, P., Stewart, S.L., Birchwood, M., Fowler, D., Gumley, A.I., Jones, P.B., . . . Dunn, G. (2012). Early detection and intervention evaluation for people at risk of psychosis: multisite randomised controlled trial. BMJ, 344.
van der Gaag, M., Nieman, D.H., Rietdijk, J., Dragt, S., Ising, H.K., Klaassen, R.M., Koeter, M., . . . Linszen, D.H. (2012). Cognitive behavioral therapy for subjects at ultrahigh risk for developing psychosis: a randomized controlled clinical trial. Schizophrenia Bulletin, 38(6), 1180-8.